About AdvanCell
AdvanCell is a company based in Sydney (Australia) founded in 2019 by Andrew Adamovich. AdvanCell has raised $444.42 million across 5 funding rounds from investors including Abingworth, Department of Health, Disability and Ageing and SV Health Investors. AdvanCell offers products and services including Alpha 212. AdvanCell operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, Ariceum Therapeutics and Lantheus, among others.
- Headquarter Sydney, Australia
- Founders Andrew Adamovich
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Advancell Isotopes Pty Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$444.42 M (USD)
in 5 rounds
-
Latest Funding Round
$315 M (USD), Series D
Jun 30, 2026
-
Investors
Abingworth
& 16 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AdvanCell
AdvanCell offers a comprehensive portfolio of products and services, including Alpha 212.
Provides cGMP isotope for targeted alpha therapy in cancer treatment development.
People of AdvanCell
Unlock access to complete
Funding Insights of AdvanCell
AdvanCell has successfully raised a total of $444.42M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $315 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AdvanCell
AdvanCell has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Abingworth, Department of Health, Disability and Ageing and SV Health Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked |
Investor details for AdvanCell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AdvanCell
Investment portfolio details for AdvanCell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AdvanCell
Detailed financials for AdvanCell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Advancell Comparisons
Peer comparison for AdvanCell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AdvanCell
AdvanCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, Ariceum Therapeutics and Lantheus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| Locked | Locked | Locked |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
|
| Locked | Locked | Locked |
Developer of diagnostic imaging agents and targeted therapeutics
|
Detailed competitors of AdvanCell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Advancell
Complete news archive for AdvanCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AdvanCell
AdvanCell was founded in 2019 and raised its 1st funding round 3 years after it was founded.
AdvanCell is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Andrew Adamovich is the current CEO of AdvanCell. They have also founded this company.
AdvanCell is a funded company, having raised a total of $444.42M across 5 funding rounds to date.
The company was founded in 2019 and is based in Sydney, Australia, within the radiopharmaceutical sector. Targeted alpha therapies for treating cancers including prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovarian types are developed. Operations center on a proprietary Pb production technology, which enables access to alpha isotopes for advancing clinical drug development.
AdvanCell's top competitors include Advanced Accelerator Applications, SOFIE and Mariana Oncology.
AdvanCell offers Alpha 212.
AdvanCell has 17 investors. Key investors include Abingworth, Department of Health, Disability and Ageing, SV Health Investors, Sanofi Ventures, and SymBiosis.